- Report
- April 2023
- 165 Pages
Global
From €6817EUR$7,500USD£5,789GBP
- Report
- February 2024
- 180 Pages
Global
From €4517EUR$4,969USD£3,835GBP
- Report
- January 2024
- 200 Pages
Global
From €3772EUR$4,150USD£3,203GBP
- Report
- August 2024
- 80 Pages
Japan
From €3181EUR$3,500USD£2,701GBP
- Report
- April 2024
- 182 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- February 2024
- 184 Pages
Global
From €4090EUR$4,500USD£3,473GBP
- Report
- April 2023
- 110 Pages
Global
From €4317EUR$4,750USD£3,666GBP
- Report
- July 2024
- 32 Pages
Global
From €632EUR$695USD£536GBP
- Report
- April 2024
- 36 Pages
Global
From €450EUR$495USD£382GBP
- Report
- August 2023
- 180 Pages
Global
From €3409EUR$3,750USD£2,894GBP
- Report
- December 2020
- 200 Pages
Global
€4045EUR$4,450USD£3,435GBP
- Report
- July 2022
- 53 Pages
Global
From €1818EUR$2,000USD£1,544GBP
- Report
- October 2023
- 230 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
The Psychedelic Drug market is a rapidly growing sector of the Mental Disorders Drugs industry. Psychedelic drugs are substances that produce altered states of consciousness, often with spiritual or therapeutic effects. These drugs are being studied for their potential to treat a variety of mental health conditions, including depression, anxiety, PTSD, and addiction.
Psychedelic drugs are being studied in clinical trials and are being used in a variety of therapeutic settings, including psychotherapy, meditation, and yoga. The potential of these drugs to treat mental health conditions has led to a surge in interest in the field, with many companies researching and developing new psychedelic drugs.
Companies in the Psychedelic Drug market include Compass Pathways, Mind Medicine, ATAI Life Sciences, Field Trip Health, and Eleusis Benefit Corporation. These companies are researching and developing new psychedelic drugs, as well as providing therapeutic services and conducting clinical trials. Show Less Read more
